A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors
Here, the authors provide a panel of medium-throughput assays to test potential drug candidates against different life cycle stages of Cryptosporidium with the goal to support a drug development pipeline that contains compounds with diverse molecular mechanisms of action.
Saved in:
Main Authors: | Rajiv S. Jumani, Muhammad M. Hasan, Erin E. Stebbins, Liam Donnelly, Peter Miller, Connor Klopfer, Kovi Bessoff, Jose E. Teixeira, Melissa S. Love, Case W. McNamara, Christopher D. Huston |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/03437c7266734301bb9d6a058e5a30f9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis
by: Christopher S. Lunde, et al.
Published: (2019) -
Suits and Uniforms
by: Hasan Kösebalaban
Published: (2004) -
Ruth Ellis’s Suit
by: Lynda Nead
Published: (2021) -
Multilocus sequence subtyping and genetic structure of Cryptosporidium muris and Cryptosporidium andersoni.
by: Rongjun Wang, et al.
Published: (2012) -
Familial Cancer Variant Prioritization Pipeline version 2 (FCVPPv2) applied to a papillary thyroid cancer family
by: Abhishek Kumar, et al.
Published: (2018)